Navigation Links
Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu

HELSINKI, November 8, 2011 /PRNewswire/ --

Valkee (, the inventor of the world's first bright light headset, and scientists from the University of Oulu present two clinical trials at the 11th IFMAD International Forum for Mood and Anxiety Disorders in Budapest on November 9th-11th. In addition, the results are published in the peer-reviewed conference supplement of the International Journal of Psychiatry in Clinical Practice.

     (Photo: )

"We presented earlier that the human brain is sensitive to light. These two clinical trials demonstrate that channeling bright light via ear canal into brain's photosensitive areas effectively prevents and treats seasonal affective disorder," comments Juuso Nissilä, Valkee's co-founder and chief scientist.

"In our first study, 92 % of the patients with seasonal affective disorder  achieved full remission measured by the self-rated BDI-21 questionnaire, during the four week study period with a daily 8-12 minute Valkee dose," comments professor Markku Timonen, MD, PhD, and the lead investigator for the two trials at the University of Oulu. The full remission criteria was BDI-21 sum score ≤ 7. The daily administration time was personalized at the study clinic.

In the presented randomized controlled trial, 89 subjects suffering from severe seasonal affective disorder had a 12-min daily Valkee dose at home in three different randomly divided groups (1, 4, 9 lumen). The response rates in the sub-groups were 74-79% for seasonal depression and 47-62% for anxiety symptoms (at least 50% reduction in BDI-21 and HAMA score, respectively, at week 4). The daily administration time was fixed to the morning, after waking up.

"These two trials show that bright light channeled into the brain via ear canal is an important future method to treat seasonal affective disorder," comments professor Timo Takala, MD, PhD, and chief physician at Oulu Deaconess Institute.

Valkee launched its bright-light headset in August 2010. Being based on cross-functional science in neurology, biology, psychiatry and physiology in University of Oulu, Finland, Valkee is a CE-certified Class II(a) medical device under the EU regulations.

The research presentation will be available for download at on Wednesday, November 9, 2011, after its scientific presentation at noon CET.

About Valkee

The Valkee ( bright light headset channels bright light direct to the human brain via the ear canal to prevent and cure depression, mood swings and circadian-rhythm disorders such as jetlag. In clinical trials, 9 of 10 patients suffering from severe seasonal affective disorder - also known as winter blues - experienced total relief from their symptoms in 4 weeks with a daily 8-12 minute dose. Valkee is based on scientific studies carried out since 2007 and is a CE-marked Class II(a) medical device. More information and for the online shop with international delivery

About the University of Oulu

The University of Oulu, one of the largest universities in Finland, is an international research and innovation university engaged in multidisciplinary basic research and academic education. The University cooperates closely with industry and commerce, and has broad connections with hundreds of international research and educational institutions. The study fields include Humanities, Education, Economics and Business, Science, Medicine, Dentistry, Health Sciences, and Technology. For more information visit

About Valkee's scientific program

Valkee ( and University of Oulu have since 2007 studied human brain photosensitivity and its therapeutic applications in curing depression and sleep disorders. Prior to these two clinical trials in seasonal affective disorder, Valkee has presented that the human brain responds to light via ear canal (fMRI data on activation of brain networks presented at ISMRM 2011) and that the human brain, not just the visual system, is sensitive to light (localization of OPN3 photoreceptor proteins broadly in 18 brain sites presented at Scandinavian Physiology Society Annual Meeting 2011).

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Duke researchers coax bright white light from unexpected source
2. Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for Best and Brightest Forum on Medical Innovation
3. Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with Best and Brightest Forum on Medical Innovation
4. New Jerseys Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development
5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
6. Light touch brightens nanotubes
7. China-Biotics Expands Product Supplied to Bright Dairy
8. Verenium to Present at MDB Capital Groups Bright Lights Conference
9. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
10. Dr. Frank Fisher of Stevens selected for Fulbright specialist roster
11. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ... Dr. Norman C.W. Wong to its Board of ... comes to Zenith with a wealth of experience as co-founder ... molecular biology. --> --> ... Zenith Epigenetics, board of directors. Zenith,s long standing expertise in ...
(Date:11/30/2015)... 2015  Champions Oncology, Inc. (CSBR), engaged in the ... the development and use of oncology drugs, today announced ... be presenting at the LD MICRO Investor Conference on ... (PST).  The conference, held at the Luxe Sunset Bel ... , will feature 200 small/micro-cap companies and is expected ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):